Overview

A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants

Status:
WITHDRAWN
Trial end date:
2032-03-30
Target enrollment:
Participant gender:
Summary
This is a study of a single systemic dose of SRP-9005 in pediatric and adult participants with limb girdle muscular dystrophy type 2C/R5 (LGMD2C/R5). It is comprised of 2 parts (Part A, Part B) that will assess safety and efficacy.
Phase:
PHASE3
Details
Lead Sponsor:
Sarepta Therapeutics, Inc.
Treatments:
Adrenal Cortex Hormones
Prednisone